


Haematologic impact of [¹⁷⁷Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore

Kim N Chi,¹ Oliver Sartor,² Karim Fizazi,³ Johann S de Bono,⁴ Neal D Shore,⁵ Ken Herrmann,⁶ Daniel Castellano,⁷ Josep M Piulats,⁸ Aude Fléchon,⁹ Xiao X Wei,¹⁰ Hyun Kim,¹¹ Michael T Schweizer,¹² Shaheen Alanee,¹³ Samson Ghebremariam,¹⁴ Marianna Hertelendi,¹⁵ Michael J Morris¹⁶

¹BC Cancer, Vancouver, BC, Canada; ²Mayo Clinic, Rochester, MN, USA; ³Gustave Roussy Institute, Paris-Saclay University, Villejuif, France; ⁴The Institute of Cancer Research and The Royal Marsden Hospital, London, UK; ⁵Carolina Urologic Research Center and GenesisCare US, Myrtle Beach, SC, USA; ⁶University Hospital Essen, Essen, Germany; ⁷Hospital Universitario 12 de Octubre, Madrid, Spain; ⁸Catalan Institute of Oncology, Barcelona, Spain; ⁹Centre Léon Bérard, Lyon, France; ¹⁰Dana-Farber Cancer Institute, Boston, MA, USA; ¹¹Washington University in St. Louis, MO, USA; ¹²University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA; ¹³Novartis Pharmaceuticals Corporation, Detroit, MI, USA; ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ¹⁵Novartis Pharmaceuticals Corporation, Basel, Switzerland; ¹⁶Memorial Sloan Kettering Cancer Center, New York, NY, USA

Figure S1. Change in absolute haematology parameters from baseline to end of treatment



ARPI, androgen receptor pathway inhibitor; EOT, end of treatment; PSMA, prostate-specific membrane antigen.